Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Foralumab in Amyotrophic Lateral Sclerosis (ALS)
NCT07688239Phase 2Enrolling by invitation
- Sponsor
- Tiziana Life Sciences
- Start
- Sep 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Foralumab with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 24 weeks and Percentage of participants that complete study treatment at 24 weeks. Started Sep 2026; status: enrolling by invitation.
02
Drugs
foralumab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07688239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688239.